RT Journal Article SR Electronic T1 A Phase II Study of Gemcitabine at Fixed Infusion Rate of 10 mg/m2/min with or without Immunotherapy in Advanced Renal Cancer JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 4461 OP 4464 VO 27 IS 6C A1 ZUSTOVICH, FABLE A1 CARTEI, GIUSEPPE A1 PASTORELLI, DAVIDE A1 NICOLETTO, ORNELLA A1 GOTTARDO, FEDRA A1 DE ZORZI, LUCA A1 BIANCO, MASSIMO DAL YR 2007 UL http://ar.iiarjournals.org/content/27/6C/4461.abstract AB Background: Advanced renal cancer remains a challenge for oncologists since no treatment other than surgery has demonstrated a clear survival advantage. Patients and Methods: Gemcitabine was given to suitable patients at a fixed infusion rate of 10 mg/m2/min. Eighteen patients received concomitant immunotherapy, mostly low doses of interleukin 2 (IL2). Results: Thirty patients were enrolled. The overall response rate was 14% (22% in the subset of patients treated with both chemotherapy and immunotherapy) with a median progression-free survival time of 4.1+ months. Toxicity was not mild, mostly fatigue, nausea and anaemia, even though not life threatening. Conclusion: Gemcitabine at the fixed infusion rate of 10 mg/m2/min with concomitant low doses of IL2 could be useful in the palliative treatment of symptomatic patients with renal carcinoma progressing after tyrosine kinases inhibitor. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved